News & Insights
Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters
Brent speaks with Senior Biopharma Correspondent Andrew Dunn for an Endpoints News feature.
Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical
Brent joins CNBC’s “Squawk Box” live in studio.
Bausch + Lomb CEO Brent Saunders on Comeback, R&D Innovation, and Eye Care’s Evolution
Brent joins the New York Stock Exchange’s “Inside the ICE House” podcast for a wide-ranging interview in advance of Bausch + Lomb Investor Day.
“CHABÁN Podcast” interview
Brent joins Alejandro Chabán for a discussion on reinvention, growth and leadership.
“Opening Bid” podcast interview
Brent joins Brian Sozzi on the Yahoo Finance “Opening Bid” podcast for a wide-ranging conversation.
Bausch + Lomb CEO: Right on track with our important initiatives
Brent joins CNBC’s “Money Movers” from the J.P. Morgan Healthcare Conference to discuss how the company has evolved in his two years as CEO and transforming the standard of care in eye health.
Bausch + Lomb CEO: the AI hysteria is nothing new
The AI arms race will be won by the companies whose people keep learning what to do with it, Brent writes for Fortune.
The Real Difference in the AI Era
Brent shares his perspective on AI leadership and organizational culture with Alan Murray for the Wall Street Journal CEO Brief.
Exclusive: Brent Saunders’ latest dermatology bet gets $20M for skin longevity
In an Endpoints News exclusive, Brent shares the premise behind Rapalogix health and the company’s plans to change how we think about skin health.
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.